Ivan Durlen

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Left atrium size and red cell distribution width predict atrial fibrillation progression from paroxysmal or persistent to permanent

Ivana Jurin, Irzal Hadžibegović, Ivan Durlen et al. · Acta Clinica Belgica · 2019 · 25 citations

The performance of the WHO COVID-19 severity classification, COVID-GRAM, VACO Index, 4C Mortality, and CURB-65 prognostic scores in hospitalized COVID-19 patients: data on 4014 patients from a tertiary center registry

Marko Lucijanić, Nevenka Piskač Živković, Tanja Režić et al. · Croatian Medical Journal · 2023 · 11 citations · Full text